Multiple Sclerosis Treatment Market

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed neurology journals, clinical trial repositories, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA) Japan, Health Canada, Therapeutic Goods Administration (TGA) Australia, and China National Medical Products Administration (NMPA). MS-specific authoritative sources comprised the National Multiple Sclerosis Society (NMSS), European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Multiple Sclerosis International Federation (MSIF), American Academy of Neurology (AAN), European Academy of Neurology (EAN), and the MS Society (UK). Clinical and epidemiological data were gathered from the National Institutes of Health (NIH/NINDS), National Center for Biotechnology Information (NCBI/PubMed), ClinicalTrials.gov, WHO Global Health Observatory, CDC National Center for Health Statistics, and EU Eurostat Health Database. Real-world evidence and prescription analytics were validated through IQVIA National Prescription Audit, Symphony Health Solutions, and Flatiron Health neurology databases. These sources were utilized to collect epidemiological statistics (diagnosed prevalent cases by EDSS scores and phenotypes), regulatory approval timelines for disease-modifying therapies (DMTs), clinical safety and efficacy data from phase III/IV trials, treatment algorithm evolution, pricing and reimbursement landscapes, and competitive intelligence across interferon-beta therapies, glatiramer acetate, anti-CD20 monoclonal antibodies (ocrelizumab, ofatumumab, ublituximab), S1P receptor modulators (fingolimod, siponimod, ozanimod), fumaric acid esters, and emerging BTK inhibitors.

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. CEOs, VPs of Neurology/Immunology R&D, global regulatory affairs chiefs, and commercial directors from pharmaceutical companies that are developing disease-modifying therapies were among the supply-side sources. Demand-side sources included board-certified neurologists (specifically MS specialists), movement disorder specialists, medical directors of infusion centers, hospital pharmacy directors, formulary committee members, and procurement leads from academic medical centers, specialty neurology clinics, and hospital systems. The market segmentation was validated across relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), and secondary-progressive MS (SPMS) populations through primary research. The product pipeline timelines for late-stage assets (Phase III/II) were confirmed, and insights on treatment paradigm shifts (early high-efficacy vs. escalation strategies), payer dynamics, and biosimilar impact on interferon and glatiramer acetate markets were gathered.

Primary Respondent Breakdown:

• By Designation: C-level Primaries (30%), Director Level (40%), Others (30%)

• By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Global market valuation was derived through revenue mapping and patient-volume analysis. The methodology included:

• Identification of 35+ key pharmaceutical manufacturers across North America, Europe, Asia-Pacific, and Latin America (including Biogen, Roche/Genentech, Novartis, Sanofi, Merck KGaA, Bayer, Teva, Bristol-Myers Squibb, Johnson & Johnson, and emerging BTK inhibitor developers)

• Product mapping across immunomodulators (interferon-beta, glatiramer acetate), immunosuppressants (cladribine, mitoxantrone), monoclonal antibodies (anti-CD20s, natalizumab), S1P receptor modulators, fumaric acid esters, and emerging neuroprotective agents

• Analysis of reported and modeled annual revenues specific to MS therapeutic portfolios, including breakdown by route of administration (oral vs. injectable/infusion) and distribution channel (hospital pharmacy vs. specialty pharmacy vs. retail)

• Coverage of manufacturers representing 80-85% of global market share in 2024 (reflecting concentrated nature of MS therapeutics market)

• Extrapolation using bottom-up (treated prevalent population × treatment penetration rates × average cost of therapy by country) and top-down (pharmaceutical revenue validation across 7MM and emerging markets) approaches to derive segment-specific valuations for interferons, monoclonal antibodies, and oral DMTs